RTP Mobile Logo
Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Targeted Therapy for Lung Cancer (Faculty Presentations)
Released April 2021

Featuring slide presentations and related discussion from Drs Joel W Neal and Paul K Paik. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.


    • Recognize the spectrum of oncogenic alterations identifiable in the epidermal growth factor receptor (EGFR) tyrosine kinase domain, and determine how these may predict response or lack thereof to EGFR-directed therapies.
    • Appreciate recently presented Phase III research supporting the efficacy of adjuvant osimertinib for patients with non-small cell lung cancer (NSCLC) with EGFR mutations after complete resection, and consider the potential effect of this information on clinical practice.
    • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC.
    • Convey the clinical relevance of a positive ROS1 mutation test result to appropriate patients with NSCLC, and appreciate available clinical research with approved and investigational agents demonstrating efficacy in such cases.
    • Assess available research with approved and emerging RET inhibitors, and use this information to guide clinical care and protocol opportunities for patients with newly diagnosed or progressive NSCLC harboring one of these abnormalities.
    • Evaluate available clinical trial findings supporting the FDA approvals of capmatinib and tepotinib for patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping, and identify individuals who might benefit from treatment with these agents.
    • Recall other oncogenic pathways (eg, HER2, NTRK, KRAS) mediating the growth of tumors in unique patient subsets, and consider published and emerging data with commercially available and experimental agents exploiting these targets.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Joel W Neal, MD, PhD
    Associate Professor of Medicine, Division of Oncology
    Stanford Cancer Institute, Stanford University
    Palo Alto, California

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Lilly, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics.

    Paul K Paik, MD
    Associate Attending Physician
    Clinical Director, Thoracic Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: Calithera Biosciences, EMD Serono Inc, Xencor; Consulting Agreements: Bicara Therapeutics, a wholly owned subsidiary of Biocon, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline; Contracted Research: EMD Serono Inc; Data and Safety Monitoring Board/Committee: Takeda Oncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Novartis.

    Release date: April 2021
    Expiration date: April 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):